Emyria Partners with Medibank to Expand Access to PTSD Care Program

Emyria Limited (ASX: EMD) has partnered with Medibank Private (ASX: MPL), Australia’s largest private health insurer, to fund eligible customers’ access to Emyria’s Empax PTSD care program at Perth Clinic. This multi-year agreement eliminates out-of-pocket costs for qualifying patients, supporting broader access to high-quality mental health care. The Empax program integrates psychiatrist-supervised psychotherapy, personalized care coordination, and real-world data monitoring to provide tailored treatments for patients with complex trauma conditions. While treatment plans vary, similar care programs typically cost between AU$20,000 and AU$30,000.

The initiative marks the first time a major insurer has backed a psychotherapy-led PTSD program in Australia, highlighting strong validation of Emyria’s evidence-based model. Emyria also announced an AU$4 million capital raise via a share placement at AU$0.024 per share, with AU$197,000 in director participation. The partnership underscores the growing recognition of mental health needs and showcases Emyria’s potential to deliver scalable, data-driven care across Australia.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com